Baltimore Capital Management Inc. lessened its stake in CVS Health Corporation (NYSE:CVS) by 31.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,780 shares of the pharmacy operator’s stock after selling 4,400 shares during the period. Baltimore Capital Management Inc.’s holdings in CVS Health Corporation were worth $787,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in CVS. Boston Partners grew its position in CVS Health Corporation by 69.1% in the 2nd quarter. Boston Partners now owns 6,459,237 shares of the pharmacy operator’s stock valued at $519,711,000 after buying an additional 2,638,888 shares in the last quarter. Prudential Financial Inc. grew its position in CVS Health Corporation by 61.8% in the 2nd quarter. Prudential Financial Inc. now owns 2,946,531 shares of the pharmacy operator’s stock valued at $237,078,000 after buying an additional 1,125,400 shares in the last quarter. Canada Pension Plan Investment Board grew its position in CVS Health Corporation by 89.8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,851,099 shares of the pharmacy operator’s stock valued at $148,939,000 after buying an additional 876,027 shares in the last quarter. Veritas Asset Management LLP grew its position in CVS Health Corporation by 11.4% in the 2nd quarter. Veritas Asset Management LLP now owns 8,438,564 shares of the pharmacy operator’s stock valued at $678,967,000 after buying an additional 865,756 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. grew its position in CVS Health Corporation by 141.2% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 1,427,210 shares of the pharmacy operator’s stock valued at $114,832,000 after buying an additional 835,476 shares in the last quarter. Hedge funds and other institutional investors own 82.04% of the company’s stock.

Shares of CVS Health Corporation (CVS) opened at $70.68 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. The company has a market cap of $71,170.00, a PE ratio of 12.34, a price-to-earnings-growth ratio of 1.21 and a beta of 0.86. CVS Health Corporation has a 52 week low of $66.45 and a 52 week high of $84.72.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. The business had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. CVS Health Corporation had a net margin of 2.77% and a return on equity of 16.96%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.64 earnings per share. equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, November 3rd. Stockholders of record on Tuesday, October 24th were given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date of this dividend was Monday, October 23rd. CVS Health Corporation’s dividend payout ratio (DPR) is 41.32%.

In other news, EVP Thomas M. Moriarty sold 20,547 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total value of $1,667,799.99. Following the completion of the sale, the executive vice president now directly owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas M. Moriarty sold 90,267 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the completion of the sale, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The disclosure for this sale can be found here. Insiders sold 714,125 shares of company stock valued at $58,119,381 over the last three months. 0.61% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/18/baltimore-capital-management-inc-sells-4400-shares-of-cvs-health-corporation-cvs.html.

A number of equities analysts recently issued reports on CVS shares. SunTrust Banks, Inc. set a $85.00 target price on shares of CVS Health Corporation and gave the company a “buy” rating in a research report on Thursday, October 12th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $95.00 target price on shares of CVS Health Corporation in a research report on Monday, October 9th. Mizuho set a $90.00 target price on shares of CVS Health Corporation and gave the company a “buy” rating in a research report on Tuesday, October 24th. Cowen and Company set a $86.00 target price on shares of CVS Health Corporation and gave the company a “buy” rating in a research report on Sunday, October 29th. Finally, Needham & Company LLC upgraded shares of CVS Health Corporation from a “hold” rating to a “buy” rating and increased their target price for the company from $69.02 to $79.00 in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $85.82.

CVS Health Corporation Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.